AnPac Bio-Medical Science Co., Ltd. (ANPC) stock prices were up by 3.08% as of the market closing on May 24th, 2021, bringing the price per share up to USD$4.68 at the end of the trading day. Subsequent pre-market fluctuations saw the stock skyrocket by 19.87%, bringing it up to USD$5.61.
Joint Venture Approved
The company’s board of directors approved the establishment of a joint venture that will work to develop new cancer treatment technology and associated products. ANPC’s contribution to the joint venture will be in the form of two filed patent applications in the cancer treatment space. Shareholder percentages of the investors involved in the joint venture will be determined based on the value of the patent applications, as assessed by an independent appraisal firm.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Read More
Basis of New Technology
The innovative technology that treats cancer will be based on ANPC’s key findings over the past decade of extensive early-stage work in cancer detection. The work done over that time period involved over 222,200 samples, with the new cancer treatment technology also being based on correlations found between change in biophysical properties in the micro-environment and cancer occurrence, as observed by various research groups including ANPC.
Further Details about Cancer Treatment Technology
The new technology will utilize key treatment modules fabricated by integrated circuit technology in tandem with certain reagents. Together, they will target biophysical properties exhibiting abnormal ranges within pre-cancer and cancer populations. The technology aims to prevent disease progression in patient cohorts that consist of both pre-cancer and cancer patients. Lab tests for the technology are expected to commence in the third quarter of the fiscal year 2021.
Solid Liquidity Position
ANPC reported as of December 31st, 2020 that it had cash and cash equivalents that totaled USD$462,000, granting the company a solid liquidity position. Cash burn for the fiscal year 2020 was USD$(9.4) million and was nearly offset in its entirety by the USD$9.3 million in cash generated from financing. ANPC has raised funds as a result of selling equity as well as by taking on debt over the course of fiscal 2021 so far. The company expects cash from financing year to date to be USD$3.6 million, based on disclosures in Form 20-F.
Future Outlook for ANPC
Armed with a solid liquidity position, ANPC is poised to capitalize on the development and eventual commercialization of the new cancer treatment technology being developed by the joint venture. Current and potential investors are hopeful that the company will continue to leverage the resources at its disposal to facilitate significant and sustained increases in shareholder value.
